Comparison
Amycretin vs. Cagrilintide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
1415456-99-3
Molecular weight
no data
4253.7 g/mol
Half-life
no data
168 h
Sequence
no data
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYMechanism of action
Amycretin
Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
3
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Amycretin and Cagrilintide?
- Amycretin is classified as "Metabolic", while Cagrilintide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Amycretin or Cagrilintide?
- The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Cagrilintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Amycretin and Cagrilintide in Germany and the United States?
- Germany: Amycretin — Unapproved, Cagrilintide — Unapproved. United States: Amycretin — Unapproved, Cagrilintide — Unapproved. These are factual summaries with source and review date on the individual pages.